A Pilot Study to Determine the Effects of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Phase of Trial: Phase I/II
Latest Information Update: 23 Aug 2018
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Biomarker; Therapeutic Use
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 05 Mar 2018 Planned End Date changed from 1 Dec 2018 to 1 Dec 2020.
- 05 Mar 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.